Patents Assigned to Health Research, Inc.
  • Publication number: 20210008194
    Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.
    Type: Application
    Filed: September 28, 2020
    Publication date: January 14, 2021
    Applicants: NATIONAL HEALTH RESEARCH INSTITUTES, FUJIFILM IRVINE SCIENTIFIC, INC.
    Inventors: Jenny BANG, Hsiao-Tzu NI, Alan Yung-Chih HU, Tsai-Chuan WENG
  • Publication number: 20200323972
    Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2.
    Type: Application
    Filed: June 3, 2020
    Publication date: October 15, 2020
    Applicant: Health Research, Inc.
    Inventor: Yi-Pin LIN
  • Patent number: 10786564
    Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: September 29, 2020
    Assignees: NATIONAL HEALTH RESEARCH INSTITUTES, FUJIFILM IRVINE SCIENTIFIC, INC.
    Inventors: Jenny Bang, Hsiao-Tzu Ni, Alan Yung-Chih Hu, Tsai-Chuan Weng
  • Patent number: 10738129
    Abstract: Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: August 11, 2020
    Assignee: Health Research, Inc.
    Inventors: Robert A. Fenstermaker, Michael J. Ciesielski
  • Patent number: 10738119
    Abstract: Provided are methods and compositions for a combination therapy for liver disorders such as hepatocellular carcinoma. Also provided is a method for determining the effectiveness of therapy involving tyrosine kinase inhibitors such as sorafenib. The method comprises determining the status of PD-1 on T cells, and based on a change in the level of PD-1 on certain cells, a determination of the effectiveness of the tyrosine kinase, and an indication for a combination therapy comprising a lower dose of tyrosine kinase inhibitor and a PD-1 inhibitor can be made.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: August 11, 2020
    Assignee: Health Research, Inc.
    Inventor: Yasmin Thanavala
  • Patent number: 10695413
    Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 30, 2020
    Assignees: HEALTH RESEARCH, INC., LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTER
    Inventors: Yi-Pin Lin, Kaspars Tars
  • Patent number: 10624881
    Abstract: Provided are methods for inducing apoptosis of cells using quinolinol compounds. Combinations of quinolinol compounds can be used in the methods. Combinations of one or more quinolinol compound and one or more inhibitors of cell growth arrest, e.g., Nutlin3a, can also be used in the methods. Also provided are compositions comprising of one or more quinolinol compound and one or more pharmaceutically acceptable carrier. The compositions can comprise one or more quinolinol compound, one or more pharmaceutically acceptable carrier, and one or more inhibitors of cell growth arrest, e.g., Nutlin3a.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: April 21, 2020
    Assignee: Health Research, Inc.
    Inventor: Xinjiang Wang
  • Patent number: 10568963
    Abstract: A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 25, 2020
    Assignees: HEALTH RESEARCH, INC., HE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ravindra K. Pandey, Raoul Kopelman, Anurag Gupta, Munawwar Sajjad
  • Publication number: 20200057053
    Abstract: The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.
    Type: Application
    Filed: August 20, 2019
    Publication date: February 20, 2020
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, HEALTH RESEARCH, INC.
    Inventors: Jennifer E. Beane-Ebel, Avrum E. Spira, Marc Lenburg, Mary E. Reid, Sarah Mazzilli
  • Patent number: 10487362
    Abstract: Provided are compositions and methods for detecting in a sample the presence or absence, and/or the amount, of a small nucleolar RNA (snoRNA) HBII-52, also known as SNORD115. The compositions and methods are useful in diagnosis, prognosis, therapy recommendations, therapy, and monitoring of therapy for individuals who have a disorder that is positively correlated with elevated HBII-52, such as cancer, and particularly for prostate cancer. Kits containing primers for detecting and/or amplifying HBII-52 from a biological sample are provided. The disclosure includes a method for monitoring an individual undergoing therapy for a disorder associated with HBII-52 expression, a method for identifying an individual as a candidate for therapy with an antagonist of 5-HT2cR, and a method for therapy by administering to a subject a therapeutically effective amount of an antagonist of 5-HT2cR.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 26, 2019
    Assignee: Health Research, Inc.
    Inventors: Barbara Foster, Steven J. Seedhouse, Jason Kirk
  • Patent number: 10478086
    Abstract: The present invention includes a responsive neural stimulator having electrodes, a filter, a processor, a recording medium, an extractor for extracting instantaneous voltage amplitudes of biased oscillatory activity with asymmetrically distributed peak/trough amplitudes, and a neural stimulator connected to the processor configured to apply neural stimulation via the neural stimulator when a predetermined state of neuronal excitability is detected, a state of relatively higher neuronal excitability corresponding to a relatively lower instantaneous voltage amplitude extracted by the extractor.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: November 19, 2019
    Assignee: HEALTH RESEARCH, INC.
    Inventors: Gerwin Schalk, Peter Brunner, William G. Coon, Adriana De Pesters
  • Patent number: 10478477
    Abstract: Provided are compositions and methods for prophylaxis and/or therapy of ErbB1-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB1-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB1-positive cancer.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: November 19, 2019
    Assignee: Health Research, Inc.
    Inventors: Yuesheng Zhang, Lu Yang, Yun Li, Arup Bhattacharya
  • Publication number: 20190293660
    Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Applicants: Health Research, Inc., The Board of Regents of The University Of Texas System
    Inventors: Susan J. WONG, Pei-Yong SHI
  • Patent number: 10393746
    Abstract: The disclosure provides methods of using biomarkers to improve diagnosis of forms of prostate. The method includes testing a biological sample from an individual for a interleukin-8 (IL-8), Tumor necrosis factor alpha (TNF-?) and soluble tumor necrosis factor-? receptor 1 (sTNFR1), and may further include testing for prostate serum antigen (PSA). Use of these markers in combination provides tests that are more sensitive and specific than PSA in differentiating benign versus malignant prostate disease and/or localized CaP versus metastatic CaP and show that the specificity and sensitivity of a PSA-based CaP diagnosis can be significantly enhanced by measuring IL-8, TNF-? and sTNFR1.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 27, 2019
    Assignee: Health Research, Inc.
    Inventors: Kailash Chadha, Willie Underwood, Austin Miller
  • Patent number: 10366780
    Abstract: A predictive system and method for using a physician's existing patient database to more effectively and efficiently identify potential candidates for medical treatments or clinical research trials. The system and method includes an automated three-tiered qualification process using information about a specific medical treatment received from a company looking for potential candidates for the medical treatment wherein potential candidates are initially prequalified by comparing the information about the medical treatment to the information contained in a physician's patient database. The potential candidates that are identified by the first tier of the qualification process then answer additional questions from a patient screening survey. Finally, additional questions from a physician consultation questionnaire are completed by the referring physician's office.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: July 30, 2019
    Assignee: ELLIGO HEALTH RESEARCH, INC.
    Inventors: Thomas Dorsett, Tushar Jain
  • Patent number: 10344052
    Abstract: Provided are peptides, fusion proteins which include the peptide sequences, compositions comprising such peptides and fusion proteins, and methods for making and using the compositions. The peptides are characterized as being able to selectively bind to components of the endothelial compartment that are exposed during the period between 1 and 7 days after androgen deprivation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 9, 2019
    Assignee: Health Research, Inc.
    Inventors: Gary Smith, Ryan Willard
  • Publication number: 20190201516
    Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 4, 2019
    Applicant: Health Research, Inc.
    Inventors: Yi-Pin LIN, Kaspars TARS
  • Patent number: 10316072
    Abstract: A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-?B-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: June 11, 2019
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, HEALTH RESEARCH, INC.
    Inventors: Xiang-Yang Wang, Xiaofei Yu, John R. Subjeck
  • Publication number: 20190160028
    Abstract: Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.
    Type: Application
    Filed: June 23, 2017
    Publication date: May 30, 2019
    Applicants: HEALTH RESEARCH, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Hongmin LI, Laura D. KRAMER, Zhong LI, Ruili HUANG, Menghang XIA
  • Patent number: 10297169
    Abstract: An intubation simulator and method are disclosed. The simulator includes a human mannequin with a mouth and a sensorized conduit. A glide scope disposed in the sensorized conduit. A first manipulator and a second manipulator are connected to the glide scope by way of a linkage. A method for simulating intubation is disclosed, where an intubation simulator is provided, computer-based instructions are provided to cause a first and second manipulator of the simulator to simulate the haptic environment of a human through the glide scope. A sensorized conduit of the simulator is used to sense a position of a tracheal tube being placed during the simulated intubation.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: May 21, 2019
    Assignee: Health Research, Inc.
    Inventors: Khurshid Guru, Ashirwad Chowriappa